Actively Recruiting
Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease
Led by Hôpital le Vinatier · Updated on 2025-07-24
120
Participants Needed
2
Research Sites
334 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower concentrations of neurofilaments in CSF of psychiatric patients compared to neurodegenerative diseases. The main objective of this study is to validate the plasma assay of neurofilament light chain as a biomarker for the differential diagnosis of psychiatric or neurodegenerative cognitive impairment. Other biomarkers of interest (Tau, TDP-43, GFAP and UCH-L1) will also be analyzed. A sub-part of this study will also focus on the retrospective analysis of the CSF/Plasma correlations of the different biomarkers mentioned above from tube bottom samples taken in routine care.
CONDITIONS
Official Title
Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provided written consent
- Diagnosed with schizophrenia according to DSM-V criteria, with or without cognitive impairment
- Diagnosed with bipolar disorder according to DSM-V criteria, with or without cognitive impairment
- Diagnosed with probable or definite frontotemporal dementia according to Rascovsky criteria 2011
- Diagnosed with biological Alzheimer's disease with typical cerebrospinal fluid profile according to NIA-AA 2011
You will not qualify if you...
- Unable to be interviewed or missing medical history
- History of recent or past head trauma with loss of consciousness
- History of ischemic or hemorrhagic stroke
- Chronic alcoholism or chronic drug use
- Progressive somatic illness, severe metabolic disorder, or poorly controlled epilepsy
- Age younger than 45 years
- Age older than 80 years
- Electroconvulsive therapy within the past 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
HCL Consultation mémoire Neurologique -Hôpital Neurologique
Bron, France, 69677
Actively Recruiting
2
Centre Hospitalier Le Vinatier
Bron, France, 69678
Actively Recruiting
Research Team
D
Dorey Jean-Michel, MD,PHD
CONTACT
S
SARTELET lydie
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here